Press Release

View printer-friendly version << Back

Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress

-- Late Breaking Presentation of Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne –

-- Presentations on MoveDMD Clinical Results and Polaris DMD Phase 3 Design –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 19, 2018-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will share three presentations, including in the late breaking session, at the 23rd International Congress of the World Muscle Society, being held October 2 – 6, 2018, at the Intercontinental Hotel in Mendoza, Argentina. Presentations include:

  • Late breaking clinical data demonstrating the potential of MRI T2 to be a marker for clinical outcome in DMD, titled “A Composite of MRI T2 of Five Lower Leg Muscles Is Highly Correlated with Timed Function Tests and Functional Status and Supports Positive Effects of Edasalonexent in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy,” will be available in the late breaking poster session throughout the conference.
  • Phase 3 PolarisDMD clinical trial design, titled “Edasalonexent, an Oral NF-kB Inhibitor, in Development for Treatment of Duchenne Muscular Dystrophy: The Phase 3 PolarisDMD Study Design,” will be presented in Poster Session 2 on Wednesday, October 3, 2018 from 16:00 to 17:30 local time.
  • Phase 2 MoveDMD trial and open-label extension data following 72 weeks of edasalonexent treatment, titled “Edasalonexent, an NF-kB Inhibitor, Slows Disease Progression Over More Than a Year Compared to Control Period in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy,” will be presented in Poster Session 2 on Wednesday, October 3, 2018 from 16:00 to 17:30 local time.

About Edasalonexent
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential new standard of care for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, which is the key link between loss of dystrophin and disease progression. NF-kB has a fundamental role in skeletal and cardiac muscle disease in DMD. Catabasis is preparing to initiate a single global Phase 3 trial, the PolarisDMD trial, in the second half of 2018 to evaluate the efficacy and safety of edasalonexent for registration purposes. Edasalonexent continues to be dosed in an open-label extension of the MoveDMD Phase 2 clinical trial. The FDA has granted orphan drug, fast track and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results reported to-date, please visit www.catabasis.com.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial is expected to initiate in the second half of 2018. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

Source: Catabasis Pharmaceuticals, Inc.

Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com